What You Should Know:
– Eyebot, the company behind the 90-second vision test kiosk that delivers doctor-verified glasses prescriptions, today announced it has raised $20 million in Series A funding. The round was led by General Catalyst, with participation from returning investors AlleyCorp, Baukunst, Village Global, and Ubiquity Ventures.
– Eyebot is redefining how people access vision care by eliminating traditional barriers like appointment delays, insurance hurdles, and inaccessibility. Its kiosks—currently in malls, universities, retail stores, and grocery chains—provide a free, 90-second vision test that can also generate a glasses prescription reviewed and verified by licensed eye doctors.
Eyebot Secures New Funding to Redefine Vision Care Access Nationwide
Eyebot is transforming the way people access vision care with its 90-second, insurance-free vision test. Patients receive prescriptions quickly, affordably, and without the hassle of appointments—while every test is reviewed by a licensed eye doctor for accuracy and clinical oversight.
Following a successful pilot phase, Eyebot has already delivered over 45,000 free vision tests since its seed round last year and is on track to exceed half a million annually. With this new round of funding, the company will:
- Expand across hundreds of new retail locations
- Scale its clinical and engineering teams
- Deepen engagement with eye care professionals
“Clear vision shouldn’t require months of waiting, high costs, or geographic luck,” said Matthias Hofmann, co-founder and CEO of Eyebot. “This funding allows us to accelerate our expansion, strengthen our clinical partnerships, and bring accessible vision care to millions more people.”
Eyebot is enhancing the in-person optical journey by making convenient, high-quality vision tests available in everyday settings such as malls, pharmacies, grocery stores, schools, and private practices. Several high-profile launches with leading retail partners are planned later this year to drive nationwide adoption.
Clinically-Sound, Doctor-Led Innovation
While Eyebot makes vision care more accessible, it is not replacing doctors—it is empowering them. Every prescription is reviewed by a licensed clinician, ensuring safety and quality. Eyebot has conducted more than 2,500 IRB-approved patient studies, demonstrating accuracy on par with traditional in-person exams. Its doctor-reviewed prescriptions consistently achieve higher satisfaction scores than the industry average.
To support its doctor-led approach, Eyebot has established a Clinical Advisory Board, chaired by Chief Medical Officer Dr. Alexander Martin, and composed of leaders from both optometry and ophthalmology. This board will guide the company’s clinical oversight as it scales nationwide.
Closing the Vision Care Gap
In the United States, more than 3 million people live with vision impairment, while 8 million more are affected by uncorrected refractive error such as nearsightedness. Millions delay or avoid care due to cost, long wait times, or lack of nearby providers.
Eyebot addresses this access gap by placing vision testing where people already are—enabling retailers to expand services with minimal footprint, supporting online eyewear brands entering physical storefronts, and helping established brick-and-mortar locations boost their capacity. The result is a new, scalable model for delivering affordable, doctor-supervised vision care nationwide.
